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The human adaptor SARM negatively regulates adaptor
protein TRIF–dependent Toll-like receptor signaling
Michael Carty1, Rory Goodbody1, Martina Schro¨der1, Julianne Stack1, Paul N Moynagh2 & Andrew G Bowie1
Toll-like receptors discriminate between different pathogen-associated molecules and activate signaling cascades that lead to
immune responses. The specificity of Toll-like receptor signaling occurs by means of adaptor proteins containing Toll–interleukin
1 receptor (TIR) domains. Activating functions have been assigned to four TIR adaptors: MyD88, Mal, TRIF and TRAM. Here
we characterize a fifth TIR adaptor, SARM, as a negative regulator of TRIF-dependent Toll-like receptor signaling. Expression
of SARM blocked gene induction ‘downstream’ of TRIF but not of MyD88. SARM associated with TRIF, and ‘knockdown’
of endogenous SARM expression by interfering RNA led to enhanced TRIF-dependent cytokine and chemokine induction.
Thus, the fifth mammalian TIR adaptor SARM is a negative regulator of Toll-like receptor signaling.
It is now well established that Toll-like receptors (TLRs) are pivotal in
initiating the early innate immune response and in directing the later
adaptive immune response1. Activation of TLRs by pathogen-
associated molecular patterns such as lipopolysaccharide (LPS; a
ligand for TLR4) or viral double-stranded RNA (a ligand for TLR3)
triggers signaling cascades that alter gene expression, which is required
for effective pathogen-specific immune responses. TLR engagement
activates several transcription factors, including NF-kB, interferon-
regulatory factor 3 (IRF3), IRF5 and IRF7, which in turn activate
many genes encoding immunoregulatory molecules, including type I
interferons, chemokines and inflammatory cytokines2.
A key feature of the TLR family, which now has 13 members
identified in mammals, is the presence of the conserved cytosolic
protein motif TIR (Toll–interleukin 1 receptor (IL-1R)) domain
through which TLRs mediate ‘downstream’ signaling. Extensive
research over the past 5 years has demonstrated much about the
molecules involved in intracellular TLR signaling. TIR domain–
containing adaptor proteins are initially recruited to receptors. The
specificity of signaling by distinct TLRs is achieved in part through
alternate and combinatorial adaptor usage. Five such adaptor proteins
have been identified, and so far four of those, MyD88, Mal, TRIF and
TRAM3, have been assigned distinct functions.
MyD88, the first adaptor to be discovered, is required for signaling
by all TLRs except TLR3 (ref. 4). IL-1R also uses MyD88 and its
downstream signaling components. IL-1R-associated kinases are serine-
threonine kinases recruited to TLR-MyD88 complexes and are required
for subsequent activation of the adaptor molecule TRAF6, which
results in activation of downstream NF-kB and mitogen-activated
protein kinases3. For TLR7 and TLR9, which respond to viral single-
stranded RNA and CpG DNA, respectively, activation of MyD88 can
also lead to IRF activation2. Although the responses to IL-1 and many
TLR agonists are completely impaired in MyD88-deficient mice, for
LPS-TLR4 some signals are intact, such as late-phase NF-kB activation
and stimulation of the interferon pathway through IRF3 activation5.
The discovery of the second TIR adaptor, Mal (also called TIRAP),
suggested a candidate TLR4 adaptor for mediation of MyD88-
independent signaling6,7. However, the phenotype of Mal–deficient
mice is similar to that of MyD88-deficient mice for both TLR2 and
TLR4 agonists, leading to the placement of Mal on the MyD88-specific
pathway for those two TLRs5. As with the other adaptors, TRIF
expression activates NF-kB, but unlike Mal and MyD88, TRIF also
induces the promoter of the gene encoding interferon-b (Ifnb)8,9. That
result raised the possibility that TRIF is the adaptor in the TLR4-
MyD88–independent pathway as well as the ‘missing’ adaptor for TLR3
and would thus mediate activation of both NF-kB and IRF3. Subse-
quently, the generation of TRIF-deficient and TRIF-mutant mice has
conclusively linked TRIF to TLR3 and also to the MyD88-independent
component of the TLR4 pathway4,10. The fourth TIR adaptor, TRAM,
is specific for TLR4 and functions ‘upstream’ of TRIF in the induction
of MyD88-independent signaling11.
The fifth member of this adaptor family, SARM, is a 690–amino
acid protein that is highly conserved in Caenorhabditis elegans,
drosophila and mammals12, yet it has no known function in mam-
malian systems3. The C. elegans ortholog of SARM, TIR-1, has been
assigned a function in worm immunity and in development. RNA-
mediated interference of TIR-1 mRNA in C. elegans leads to dimin-
ished worm survival in response to fungal infection, partly due to
reduced expression of the antimicrobial peptides NLP-29 and NLP-31
(ref. 13). Similar findings14 have shown that the C. elegans p38
mitogen–activated protein kinase PMK-1, which is important in
worm immunity, requires TIR-1 for activation. TIR-1 is also involved
in C. elegans development, specifically in the asymmetric expression of
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odorant receptors of olfactory neurons15. Those results suggest a
positive function for TIR-1 in C. elegans immunity. In contrast,
however, a comparative study of the five mammalian adaptors has
shown that mammalian SARM fails to activate NF-kB, unlike the
other four adaptors14.
Here we report that human SARM functions as a specific inhibitor
of TRIF-dependent signaling, transcription factor activation and gene
induction. We also identify the sequence motifs in SARM required for
the inhibitory function and demonstrate that SARM and TRIF
interact. Notably, small interfering RNA (siRNA) targeting of SARM
mRNA led to enhanced TLR3- and TLR4-dependent gene induction in
both transformed and primary human cells. Thus, we demonstrate an
important function for SARM as a TRIF-specific inhibitory protein.
RESULTS
SARM expression downregulates TRIF-dependent NF-jB
Given that SARM is a cytosolic TIR domain–containing protein, we
sought to determine whether it functions like other TIR domain–
containing proteins. We first compared the ability of SARM and TRIF
to drive transcription factor activation and gene induction. Consistent
with published reports14,16, we found that although overexpression of
TRIF led to activation of NF-kB and IRF3, expression of SARM had
little or no effect (Fig. 1a,b). In agreement with those results, TRIF
expression led to induction of the Ccl5 (RANTES) promoter, which
requires NF-kB and IRF3 activation (Fig. 1c), whereas SARM expres-
sion, which we confirmed by immunoblot (Fig. 1d), did not activate
the Ccl5 promoter (Fig. 1c). Although expression of SARM did not
lead to NF-kB activation, stimulation of TLR4 signaling by means of
LPS treatment strongly enhanced endogenous SARM expression in
primary human peripheral blood mononuclear cells (PBMCs; Fig. 1e).
That observation led us to explore alternative functions for SARM in
TLR signaling pathways.
In particular, we investigated whether SARM has a negative reg-
ulatory function, similar to that of the membrane-bound TIR
domain–containing proteins SIGIRR and ST2, both of which are
involved in the downregulation of IL-1R and TLR4 signaling17,18. All
IL-1R–TLR family members except TLR4 signal via MyD88 or TRIF;
TLR4 signals via both. We therefore examined the effect of SARM
expression on signaling pathways emanating from MyD88 and TRIF.
MyD88-induced NF-kB activation was unaffected by SARM expres-
sion (Fig. 2a), whereas TRIF-induced NF-kB was inhibited in a
dose-dependent way by SARM expression (Fig. 2b). Consistent with
the lack of effect on the MyD88 pathway, there was also a lack of effect
on Mal, which functions upstream of MyD88 in TLR4 signaling
(Fig. 2c). We also noted apparently selective inhibition of the TRIF
but not the MyD88 pathway for ligand-induced NF-kB activation:
IL-1-induced NF-kB activation, which is mediated exclusively by
MyD88, was unaltered by SARM expression (Fig. 2d), whereas
TLR3-dependent polyinosinic-polycytidylic acid (poly(I:C))–induced
NF-kB, which is entirely TRIF dependent, was potently blocked by
SARM expression (Fig. 2e). In addition to a critical function in TLR
signaling, NF-kB activation is also a hallmark of tumor necrosis factor
(TNF) and RNA helicase RIG-I signaling19; neither of those pathways
was affected by SARM (Fig. 2f,g). Thus, inhibition of NF-kB by
SARM expression is restricted to the TRIF pathway.
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Figure 2 SARM inhibits TRIF dependent NF-kB activation. (a–c) Luciferase assay of HEK293
cells transfected with the NF-kB reporter and 25 ng of a MyD88 expression plasmid (a), 10 ng
of a TRIF expression plasmid (b) or 50 ng of a Mal expression plasmid (c) along with SARM
expression plasmid (amount (in ng), horizontal axes). (d–f) Luciferase assay of HEK293 cells (d,f)
or HEK-TLR3 cells (e) transfected with the NF-kB reporter and SARM expression plasmid
(amount (in ng), key) and stimulated for 6 h with 100 ng/ml of IL-1 (d), 25 mg/ml of poly(I:C) (e)
or 100 ng/ml of TNF (f). (g) Luciferase assay of HEK293 cells transfected for 24 h with the
NF-kB reporter and SARM expression plasmid and a RIG-I expression plasmid. Experiments are
one of three repeats (error bars, s.d.).
Figure 1 Expression of SARM fails to activate NF-kB or IRF3.
(a–c) Luciferase assay of HEK293 cells transfected for 24 h with
1–100 ng Flag-tagged SARM or 10 ng TRIF along with reporter constructs
for NF-kB (a), IRF3 (b) or the Ccl5 promoter (c). (d) Immunoblot for
expression of Flag-tagged SARM in HEK293 cells (top). NS, nonspecific.
Wedge indicates increasing concentration of cDNA transfected. Bottom,
immunoblot reprobed with anti-b actin (loading control). (e) Immunoblot (IB)
for SARM in lysates of PBMCs treated with LPS (time, above lanes).
Experiments are one of two repeats (error bars, s.d.).
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SARM inhibits induction of TLR4- and TLR3-dependent genes
We next examined the effect of SARM on TRIF-dependent signaling
and chemokine induction in more detail. TLR3 induces genes exclu-
sively via TRIF. Treatment of TLR3-expressing HEK293 cells (called
‘HEK-TLR3’ cells here) with poly(I:C) led to RANTES production that
was inhibited in a dose-dependent way by SARM expression, whereas
SARM alone had no effect on basal RANTES expression (Fig. 3a, left).
Poly(I:C) can also signal through engagement of the double-stranded
RNA–dependent protein kinase PKR and RIG-I, both of which are
located in the cytoplasm20,21. To determine the effect of SARM on
those pathways, we used HEK293 cells lacking TLR3 expression; we
transfected the cells with poly(I:C) and then assessed RANTES
production. In contrast to the effect of SARM on TLR3-dependent
gene induction, TLR3-independent RANTES production was mostly
unaltered by transient SARM expression (Fig. 3a, right).
We next demonstrated that the effect of SARM on TLR3-dependent
gene induction was at or upstream of the level of promoter activation.
SARM expression potently inhibited TLR3-induced activation of both
the Ccl5 and Ifnb promoters (Fig. 3b). Both promoters are dependent
on activity of the transcription factors NF-kB and IRF3. As well
as inhibiting TLR3-dependent NF-kB activation (Fig. 2e), SARM
expression also inhibited poly(I:C)-induced activation of the inter-
feron-stimulated responsive element but not RIG-1-stimulated activa-
tion of IRF3 (data not shown), which indicated the specificity of the
SARM inhibitory effect on the TLR3 pathway for poly(I:C).
Because TLR4 also uses TRIF for signaling to NF-kB and IRF3, we
next tested whether TLR4 signaling was also suppressed by SARM.
Similar to the results obtained for TLR3, LPS-TLR4–induced RANTES
production was also potently inhibited by SARM expression (Fig. 3c).
RANTES production by TLR4 is known to be entirely TRIF depen-
dent11. We obtained further evidence that SARM suppresses TRIF-
specific signaling by examining induction of the TLR4-TRIF-IRF3–
dependent promoters Ccl5 (Fig. 3d) and Ifnb (Fig. 3e) and by
assessing LPS-induced IRF3 activation (Fig. 3f); all of those were
potently blocked by SARM expression.
SARM blocks TRIF-IRF7 but not MyD88-IRF7
IRF7 has been shown to be the ‘master regulator’ of interferon
induction in response to diverse viruses22. IRF7 functions to upregu-
late interferon-a/b production, thus limiting the spread of viral
infection. IRF7 can be activated by TLR3 and TLR4 via TRIF11 or
by TLR9 via MyD88 (refs. 23,24). Because of the functional impor-
tance of IRF7 and the fact that IRF7 can be activated by means of two
distinct adaptors, we tested whether SARM could modulate the two
TLR-IRF7 axes. Similar to the other TRIF-dependent signals, SARM
inhibited TRIF-induced IRF7 activation in a dose-dependent way
(Fig. 4a). However, SARM exerted no inhibition on MyD88-induced
IRF7 activation (Fig. 4b). The strength of those observations was
further emphasized by experiments with RAW264.7 cells in which
IRF7 activation by treatment with poly(I:C) or LPS was reduced
substantially by SARM expression (Fig. 4c). The last observation
eliminated the possibility that the inhibitory effect exerted by SARM
was solely HEK293 dependent.
SARM targets TRIF
The observations reported above raised the possibility that the adaptor
TRIF was being directly targeted by SARM. Similar to the situation
with TRIF-induced NF-kB activation (Fig. 2b), RANTES release, Ccl5
(RANTES) promoter induction and IRF3 activation were all inhibited
by SARM in a dose-dependent way (Fig. 5a–c). To confirm that the
observed inhibition was specific to TRIF-related functions, we exam-
ined the sensitivity to SARM of upstream regulators and downstream
effectors of TRIF. The TIR domain–containing adaptor TRAM acts as
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Figure 3 SARM inhibits TLR3- and TLR4-dependent gene induction. (a) ELISA of RANTES production
by HEK-TLR3 cells transfected for 24 h with SARM expression plasmid (amount (in ng), key) or vector
control, then treated with 25 mg/ml poly(I:C) treatment (left), and TLR3-independent RANTES produc-
tion in HEK293 cells transfected with poly(I:C) (right). (b) Luciferase assay of HEK-TLR3 cells trans-
fected with SARM expression plasmid (key, in ng) and the Ccl5 promoter reporter plasmid (left) or Ifnb
promoter reporter plasmid (right); after 24 h, cells were treated for 6 h with 25 mg/ml of poly(I:C).
(c) ELISA of RANTES in supernatants from HEK-TLR4 cells transfected for 24 h with increasing
amounts of SARM (key, in ng) or vector and then stimulated for 24 h with 1mg/ml of LPS. (d,e) Luciferase assay of HEK-TLR4 cells transfected for
24 h with increasing amounts of SARM (key, in ng) or vector along with the Ccl5 promoter reporter (d) or Ifnb promoter reporter (e). (f) Luciferase assay of
HEK-TLR4 cells transfected for 24 h with Gal4-IRF3 and the pFR-luciferase reporter in conditions similar to those in d,e. Experiments are one of three
repeats (error bars, s.d.).
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Figure 4 SARM inhibits IRF7 activation by the TRIF but not by the MyD88
pathway. (a,b) Luciferase reporter assay of IRF7 activation in HEK293 cells
transfected for 24 h with 10 ng TRIF expression plasmid (a) or 25 ng
MyD88 expression plasmid (b) and increasing amounts of SARM expression
plasmid (key, in ng). (c) Luciferase reporter assay of IRF7 activation in
RAW264.7 cells transfected for 24 h with 100 ng SARM expression
plasmid or vector and then stimulated for 6 h with either 25 mg/ml of
poly(I:C) or 1 mg/ml of LPS. Experiments are one of three repeats (a,b)
or one of two repeats (c); error bars, s.d.
1076 VOLUME 7 NUMBER 10 OCTOBER 2006 NATURE IMMUNOLOGY
A R T I C L E S
©
20
06
 
N
at
ur
e 
Pu
bl
is
hi
ng
 G
ro
u
p 
 h
ttp
://
w
w
w.
n
at
ur
e.
co
m
/n
at
ur
ei
m
m
u
n
o
lo
gy
a bridge connecting TLR4 to TRIF and facilitates TRIF dependent
signaling4,11. TRAM is thought to mediate signaling exclusively
through TRIF. We found that activation of the Ifnb promoter by
expression of TRAM was potently blocked by SARM expression
(Fig. 5d). Two critical downstream mediators of TRIF signaling are
RIP1 and TBK1, which are involved in activation of NF-kB and IRF3,
respectively25,26. However, ‘forced’ expression of RIP1 (Fig. 5e) or
TBK1 (Fig. 5f) leading to stimulation of NF-kB or IRF3 activation,
respectively, was not affected by SARM expression (Fig. 5e,f).
Furthermore, SARM had no effect on TRAF6-induced signaling
(data not shown); TRAF6 is an important mediator of NF-kB
activation downstream of both TRIF and MyD88.
The data we have reported thus far have provided compelling
evidence that SARM acts at the level of TRIF. Given the presence of
the TIR homotypic interaction domain in both TRIF and SARM,
we speculated that SARM inhibition of TRIF might be achieved by
direct interaction. To test that possibility, we did coimmunoprecipita-
tion experiments in HEK-TLR3 and HEK-TLR4 cells. Overexpressed
TRIF and SARM were immunoprecipitated together in both cell
lines (Fig. 5g and data not shown). In
HEK-TLR4 cells, we detected hemaggluti-
nin-tagged TRIF in FLAG-tagged SARM
immunoprecipitates (Fig. 5g, top, lane 2).
The interaction between TRIF and SARM
was enhanced, furthermore, after 15 min of
LPS stimulation (Fig. 5g, top, lane 3), most
likely because of higher SARM expression in
the presence of LPS (Fig. 5g, middle). Given
that human primary PBMCs expressed endo-
genous SARM (Fig. 1e), we next attempted
to demonstrate an interaction between endo-
genous SARM and TRIF in those cells. We
detected a small amount of TRIF in endo-
genous SARM immunoprecipitates in the
absence of LPS (Fig. 5h, top, lane 1), and
the amount of TRIF detected increased after a
10 min LPS treatment (Fig. 5h, top, lane 2),
which again was consistent with an increase
in SARM expression in the presence of LPS
(Fig. 5h, bottom).
To obtain evidence of interaction by an
independent approach and to confirm that
the observed interaction between TRIF and
SARM was direct, we used a pairwise yeast
two-hybrid assay. Yeast transformed with
both the vector bearing the SARM binding
domain and the vector bearing the TRIF
activation domain thrived on agar lacking
histidine and on agar lacking both histidine
and adenine. The ability of auxotrophic yeast
strain to grow on the deficient medium was
made possible by the interaction of TRIF and
SARM, thus reconstituting the yeast tran-
scription factor Gal4, leading to expression
of the Gal4-responsive genes His3 and Ade
(Fig. 5i, middle and right). As a negative
control, we transformed yeast with the SARM
binding domain and the vaccinia TIR
domain–containing protein A46R; these
failed to interact (Fig. 5i). That result was
consistent with published data demonstrating
a lack of interaction between SARM and A46R in coimmunoprecipi-
tation experiments27.
Inhibition requires the sterile a-motif and TIR domains of SARM
SARM contains two well defined protein motifs: the TIR domain,
spanning amino acids 512–690, and two tandem sterile a-motif
(SAM) domains, within amino acids 371–511. It has been predicted12
that SARM contains HEAT-armadillo motifs as well; however the
existence those last motifs is more speculative. To identify the region
of SARM required for the inhibition of TRIF, we generated several
SARM truncations with different combinations of the TIR and SAM
domains (Fig. 6a). We evaluated the effects of the SARM truncations
on TRIF-dependent signaling using poly(I:C)-induced NF-kB activa-
tion in HEK-TLR3 cells as a ‘readout’. Full length SARM (as shown in
Fig. 2e) inhibited NF-kB activation in a dose-dependent way
(Fig. 6b). In contrast, a SARM construct lacking the N terminus
and SAM domains and a SARM construct lacking lacked the TIR
domain failed to cause any inhibition. SARMDN, which contained
only the TIR domain and SAM domains and lacked the N-terminal
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Figure 5 SARM associates with and inhibits TRIF signaling. (a) ELISA of RANTES production by
HEK293 cells transfected for 24 h with SARM and TRIF expression plasmids. (b,c) Luciferase assay for
Ccl5 promoter induction (b) or IRF3 activation (c) in HEK293 cells transfected for 24 h with SARM
expression plasmid (amount (in ng), horizontal axes) and TRIF expression plasmid. (d) Luciferase assay
for induction of the Ifnb promoter in HEK293 cells transfected as in b,c, but with 50 ng TRAM
expression plasmid. (e) Luciferase assay for NF-kB activation in HEK293 cells transfected as in
b,c, but with 50 ng RIP1 expression plasmid. (f) Luciferase assay for IRF3 activation in HEK293
cells transfected as in b,c, but with 50 ng TBK1. (g) Immunoprecipitation (IP) and immunoblot (IB)
analysis of lysates of HEK-TLR4 cells transfected for 36 h with hemagglutinin-tagged TRIF (HA-TRIF)
and Flag-tagged SARM. +LPS, cells treated for 15 min with 10 ng/ml of LPS; a-, antibody to.
(h) Immunoprecipitation and immunoblot analysis of lysates of human PBMCs left unstimulated (0)
or treated for 10 min with 100 ng/ml of LPS (10) and then lysed in extraction buffer. (i) Pairwise
interactions assessed in yeast cells transformed with BD-SARM and AD-TRIF or AD-A46R and grown
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adenine (–Ade). Growth on middle and right plates indicates a direct interaction. Experiments are one
of three repeats (error bars, s.d.).
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region, inhibited signaling in a dose-dependent way and was even
more potent than full-length SARM. The strength of SARMDN as an
inhibitor was further emphasized by the finding that it completely
abolished TRIF-induced NF-kB and IRF3 activation (data not shown).
Examination of the expression of full-length SARM and SARMDN
provided a rationale for the more potent inhibition obtained with the
latter: cells had lower expression of full-length protein than SARMDN
(Fig. 6c, lane 2 versus 6), whereas LPS treatment of cells for 1 h led to
an increase in the abundance of full-length SARM but not SARMDN
(Fig. 6c, lane 3 versus lane 7), an effect that was apparent even after
24 h of LPS stimulation. These data demonstrated that the TIR
domain and the two SAM domains are necessary and sufficient for
inhibition of TRIF signaling and that the N terminus, although
dispensable for TRIF inhibition, is required for LPS-induced enhance-
ment of SARM expression.
SARM suppression enhances TRIF-dependent gene induction
To determine the function of endogenous human SARM in TRIF
signaling, we ‘knocked down’ SARM1 expression using RNA-mediated
interference. In addition to the 690–amino acid form of human
SARM, a second, 724–amino acid form with an extended N-terminal
region has been reported (GenBank accession number AY444166). We
confirmed expression of endogenous SARM1 in HEK293 cells using
RT-PCR (Fig. 7a) and used two siRNA oligonucleotides, S1 and S2,
targeting both forms of human SARM1 mRNA. S1 substantially
reduced, whereas S2 completely abolished, SARM1 mRNA, whereas
a nontargeting siRNA had little effect on SARM1 expression (Fig. 7a).
Therefore, to confirm that endogenous SARM inhibited TRIF func-
tion, we examined TLR3-TRIF–dependent signaling and gene induc-
tion in the presence of S1 and S2.
Forced expression of TRIF induced the Ifnb promoter, which was
increased approximately by a factor of three in cells treated with either
S1 or S2 compared with those treated with the nontargeting control
siRNA (Fig. 7b). There was similar enhancement of Ifnb promoter
induction in the presence of S1 or S2 when we treated HEK-TLR3 cells
with poly(I:C) to trigger TLR3 signaling (Fig. 7c). It has been reported
that certain siRNA oligonucleotides can trigger TLR3 activation28.
However, in our experiments here, neither S1 nor S2 alone activated
the Ifnb promoter (Fig. 7b,c) or NF-kB (data not shown). We next
examined the effect of ‘knocking down’ SARM1 expression on
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chemokine release in response to poly(I:C). RANTES production after
poly(I:C) stimulation of HEK-TLR3 cells was enhanced
by 40% by SARM1 siRNA treatment (Fig. 7d). As a control, we
tested MyD88-dependent release of the chemokine IL-8 in response to
IL-1 stimulation; this was unaffected by ‘knockdown’ of SARM1
expression (Fig. 7e).
Finally, we tested the effect of the SARM1 siRNA oligonucleotides in
primary human PBMCs. In the conditions of poly(I:C) stimulation
used here (25 mg/ml for 24 h), we detected no RANTES release
(Fig. 7f). Treatment of the cells with S2 facilitated RANTES release to
three times above the control release (Fig. 7f). Again, S2 alone had no
stimulatory effect on the cells. Given that TRIF is essential for LPS-
induced TNF release from mouse macrophages10, we also tested the
effect of SARM1 siRNA on this response in human PBMCs. Treatment
of these cells with S2 enhanced TNF production in response to LPS by
250% (Fig. 7g). Thus, suppression of endogenous SARM1 expression
in primary human blood cells affected TLR3- and TLR4-dependent
gene induction. These results provided conclusive evidence that SARM
functions as a specific inhibitor of TRIF-dependent signaling.
DISCUSSION
Human SARM was originally identified as an ortholog of the
drosophila gene CG7915, which is highly conserved in mouse and
C. elegans12. High expression in the kidney and liver was demonstrated
and an antisense transcript was reported12. As mentioned above, in
C. elegans the SARM ortholog TIR-1 has a positive function both in
development and in immunity13–15. In contrast, we have shown here
that human SARM is a specific negative regulator of TRIF signaling
and thus of certain innate immune responses. We have also demon-
strated that SARM and TRIF interact directly. We have confirmed the
negative function of SARM using siRNA to suppress endogenous
SARM1 expression, which led to enhanced TRIF-dependent gene
induction in both transformed and primary human cells but did
not affect IL-1–MyD88–induced IL-8 production. The demonstration
of enhanced TNF production after treatment with SARM siRNA in
PBMCs has also provided evidence of the involvement of TRIF in
LPS-induced TNF production in human blood.
TRIF is critical in mediating both TLR3 and TLR4 signaling. For
example, TRIF is important in resistance to cytomegalovirus infec-
tion10, in the LPS-induced upregulation of costimulatory molecules
on antigen-presenting cells29 and in mediating the TLR4-induced cell
activation program in dendritic cells30. The importance of TRIF in the
antiviral response is emphasized by the fact that it is targeted for
immune evasion by the vaccinia virus protein A46R27 and also by the
hepatitis C virus protease NS3-4A31. Although many diverse host
mechanisms for inhibiting and regulating TLR function have been
identified, most of those (such as SIGIRR, ST2, IL-1R-associated
kinase-M, Tollip and MyD88s) seem to target the MyD88-dependent
pathway, although at least one (A20) can inhibit both MyD88 and
TRIF signaling32. Less is known about cellular inhibitors that are
specific for the TRIF pathway, yet given the central importance of
TRIF to many aspects of innate immunity, specific host regulation of
TRIF function to prevent excessive activation of its downstream
pathways might be expected. SARM thus provides an important
regulating function for the diverse activities of TRIF. The ability of
LPS to enhance SARM protein expression after just 1 h of treatment
provides a mechanism whereby TLR4 signaling could lead to a rapid
downregulation of the TRIF pathway. The SARM and TRIF associa-
tion, relatively weak in unstimulated cells, was strongly enhanced after
short LPS treatment. Poly(I:C) and LPS did not have a substantial
regulatory effect on SARM1 mRNA expression (data not shown), yet
LPS stimulation led to a rapid increase in SARM protein. The SARM
inhibitory activity, therefore, is not regulated by a change in the
amount of mRNA but instead by ligand-induced enhancement of
SARM protein expression, which in turn leads to increased interaction
of SARM and TRIF. The post-transcriptional regulation of SARM
might involve signal-dependent stabilization of the protein itself. The
finding that deletion of the N terminus of SARM enhanced its
inhibitory function and expression and reduced its sensitivity to
LPS-induced expression may suggest that SARM is inherently unstable
because of motifs in its N terminus and that LPS treatment somehow
makes the protein more stable.
Related to the issue of SARM protein stability is the case of the
C. elegans SARM homolog TIR-1, which when truncated to consist of
only the two SAM domains and the TIR domain shows a stronger
gain-of function developmental phenotype than the full-length pro-
tein15. Of further note, six forms of TIR-1 exist15. However, in all of
the splice variants, the SAM and TIR domains remain intact and vary
at the N terminus only. Those data are consistent with the ideas that
the N terminus of SARM may be regulatory in both humans and
C. elegans and that important functions are mediated by the SAM and
TIR domains.
Although we have demonstrated that ‘knockdown’ of SARM
enhanced TLR3- and TLR4-dependent responses and that TRIF and
SARM interacted, the exact mechanism whereby SARM inhibits TRIF
function is as yet unclear. One possibility is that binding of SARM to
TRIF may simply physically prevent engagement of TRIF with either
its upstream activators or its downstream effectors. Thus, SARM may
shield TRIF from contact with TRAM, in the case of TLR4, and also
prevent binding to TLR3. However, that scenario is unlikely given that
SARM can inhibit signals elicited directly from TRIF. Alternatively,
SARM may prevent TRIF from accessing its downstream signaling
molecules, TBK1, TRAF6 and RIP1, all of which interact with specific
sites on TRIF25,33.
Another possible inhibitory mechanism is that SARM recruits an
inhibitory protein (or protein complex) to TRIF. The two protein
domains identified in SARM as being necessary and sufficient for
TRIF inhibition were the TIR domain and the SAM domains. Thus,
the TIR domain of SARM may provide the specificity required to
target TRIF, whereas the SAM domains may recruit an as-yet-
unidentified TLR inhibitor. SAM domains mediate the formation of
homo- and heterodimers between different SAM domain–containing
proteins; they can also bind to various other protein interaction
motifs34. Unlike other protein domains, such as the TIR domain, no
common function is known for SAM domains. In fact, SAM domain–
containing proteins exist in all subcellular locations, are involved in
many different biological processes, bind to a wide variety of proteins
and have also been shown to bind to RNA34. Hence, it is difficult to
predict what the SAM domains of SARM may interact with. Further
studies, such as yeast two-hybrid screening, will be needed to identify a
putative inhibitor.
METHODS
Expression vectors. Plasmids used expressed the following proteins:
AU1-MyD88 (obtained from M. Muzio, Mario Negri Institute, Milan, Italy)35;
Flag-tagged SARM, TRAM, Mal, RIP1, TBK1, RIG-I, IRF3-Gal4 and IRF7-Gal4
(obtained from K. Fitzgerald, University of Massachusetts, Worcester, Massa-
chusetts)14,11,26; Flag-tagged TRIF (obtained from S. Akira, Osaka University,
Osaka, Japan); hemagglutinin-tagged TRIF (obtained from C. Basler, Mount
Sinai School of Medicine, New York, New York); and RIP1 (obtained from
J. Tschopp, University of Lausanne, Lausanne, Switzerland)25. Vectors expres-
sing various SARM truncations were made using standard PCR and cloning
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techniques; the full-length construct was used as a template. Primers used are
listed in Supplementary Table 1 online.
Antibodies and reagents. Antibody to SARM (anti-SARM) was from ProSci,
monoclonal anti–FLAG M2 was from Sigma, and anti-hemagglutinin was from
Covance. Human recombinant IL-1a was provided by the National Cancer
Institute. Human recombinant TNF was a gift from S. Foster (Zeneca
Pharmaceuticals, Macclesfield, UK). TLR agonists used were poly(I:C) (Amer-
sham Biosciences) and LPS (Alexis). Anti-TRIF was from Alexis.
Reporter gene assays. HEK293, HEK-TLR3 (ref. 11) and HEK-TLR4 cells (2
104 cells per well) or RAW264.7 cells (4  104 cells per well) were seeded into
96-well plates and were transfected 24 h later with expression vectors and
luciferase reporter genes using GeneJuice (Novagen). In all cases, 20 ng/well of
phRL-TK reporter plasmid (Promega) was cotransfected to allow normal-
ization of data for transfection efficiency. The total amount of DNA per
transfection was kept constant at 230 ng (HEK293) or 200 ng (RAW264.7) by
the addition of pcDNA3.1 (Stratagene). After 24 h, reporter gene activity was
measured27. Reporter genes used were for NF-kB27 and the Ccl5 promoter and
Ifnb promoter. For the IRF3 and IRF7 assays, 3 ng of vector expressing IRF3-
Gal4 or IRF7-Gal4 was transfected along with 60 ng of the pFR luciferase
reporter plasmid27. All reporter assays were done in triplicate and data are
expressed as ‘fold induction’ (mean ± s.d.) relative to control induction for a
representative experiment.
Measurement of cytokine concentrations. HEK293, HEK-TLR3 or HEK-
TLR4 cells were used for measurement of cytokine production. Cells (2 
104 cells per well) transfected for 24 h with the SARM1 expression plasmid were
stimulated for 24 h with 1 mg/ml of LPS or 25 mg/ml of poly(I:C). For poly(I:C)
transfection (where indicated), poly(I:C) was added to a mixture of serum-free
medium and GeneJuice and then was incubated for 15 min at 25 1C before
being transfected into cells. Supernatants were collected 24 h later and IL-8 or
RANTES concentrations were measured by enzyme-linked immunosorbent
assay (ELISA; R&D Biosystems). Experiments were done in triplicate and data
are expressed as the mean ± s.d. from one representative experiment.
‘Knockdown’ with siRNA. The siRNA was designed to target human SARM1
in two different regions (see Supplementary Table 1). For reporter gene assays,
HEK293 or HEK-TLR3 cells were seeded at a density of 3  104 cells per well in
96-well plates and were transfected 24 h later with expression vectors and
luciferase reporter genes together with siRNA, using lipofectamine 2000
(Invitrogen). The siRNA transfection was repeated 24 h later and reporter
gene activity was measured 24 h thereafter. For ELISA, HEK-TLR3 or HEK293
cells were seeded at a density of 3  104 cells per well and siRNA was
transfected twice, at 24 and 48 h after cell seeding. PBMCs from healthy donors
were isolated with Lymphoprep reagent (Axis-Shield) according to the man-
ufacturer’s instruction. Then, 2 105 cells per well were plated in 96-well plates
and cells were allowed to equilibrate for 1 h. Cells were treated with siRNA 24
and 48 h after seeding, then were treated with 25 mg/ml of poly(I:C) or 100 ng/
ml of LPS; supernatants were isolated 24 h thereafter, and RANTES or TNF
release was measured by ELISA.
RT-PCR. Total RNA from cells seeded in six-well plates was isolated with TRI
Reagent (Sigma) according to the manufacturer’s instructions. Random-primed
RNA (1 mg) was reverse-transcribed with ImPROM-II reverse transcriptase
(Promega) according to the manufacturer’s instructions. The cDNA obtained
was used in PCR with Taq DNA polymerase (Invitrogen) to determine the
relative amount of SARM mRNA (see Supplementary Table 1).
Coimmunoprecipitation and immunoblot analysis. HEK-TLR4 cells were
seeded into 175-cm2 flasks and were grown to 60% confluence before being
transfected with 8 mg of Flag-tagged SARM and hemagglutinin-tagged TRIF,
using GeneJuice. The total amount of DNA was kept constant between
transfections by the addition of pcDNA3.1. At 36 h after transfection, cells
were lysed with 1,700 ml of Nonidet-P40 extraction buffer, consisting of 50 mM
HEPES, pH 7.5, 100 mM NaCl, 1 mM EDTA, 10% (vol/vol) glycerol and 0.5%
(vol/vol) Nonidet-P40 and containing protease inhibitors. Cells were lysed on
ice for 1 h, insoluble material was removed by centrifugation and the resultant
lysates were immunoprecipitated for 2 h at 4 1C with anti–Flag M2 agarose
(Sigma). Immune complexes were washed and eluted, were separated by SDS-
PAGE and were analyzed by immunoblot with anti-hemagglutinin.
For immunoblot of PBMCs, 1.5  107 cells were seeded in 100-mm dishes
and were treated for 1–24 h with 100 ng/ml of LPS. Cells were lysed in Lamelli
sample buffer, were sonicated and boiled and were separated by SDS-PAGE. For
detection of endogenous TRIF in endogenous SARM immunoprecipitates, 3 
107 human PBMCs from buffy coats were seeded in 100-mm dishes. Cells were
left to equilibrate for 1 h at 37 1C and were then treated with 100 ng/ml of LPS.
Cells were scraped into medium and centrifuged. The resulting cell pellet was
washed twice in ice cold PBS and was lysed on ice for 1 h with 850 ml Nonidet-
P40 extraction buffer. For efficient lysis, cells were ‘syringed’ in extraction
buffer six times with a 27-gauge needle. Insoluble material was removed by
centrifugation and lysates were immunoprecipitated overnight at 4 1C with
anti-SARM. Immune complexes were washed and eluted, were separated by
SDS-PAGE and were analyzed by immunoblot with human anti-TRIF.
Yeast two-hybrid analysis. The MATCHMAKER GAL4 Two Hybrid System 3
(Clontech) was used to assess interaction between TRIF and SARM and
between SARM and A46R. The activation-domain vector pGADT7 encoding
TRIF was a gift from L. O’Neill (Trinity College, Dublin, Ireland). A46R was
cloned into pGADT7, and SARM was cloned into the bait vector pGBKT7.
Transformed AH109 yeast cells were plated onto agar lacking leucine and
tryptophan and the resultant colonies were streaked onto plates lacking leucine,
tryptophan and histidine or plates lacking leucine, tryptophan, histidine and
adenine. Plates were then incubated at 30 1C for 3–4 d and the growth of yeast
was recorded.
Note: Supplementary information is available on the Nature Immunology website.
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